Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Rhea-AI Summary
Axsome Therapeutics (NASDAQ: AXSM) provided preliminary unaudited net product revenue for Q4 and full year 2025. Total preliminary net product revenue was $196.0 million for Q4 2025 and $638.5 million for full year 2025, representing 65% and 66% annual growth, respectively. AUVELITY preliminary net product sales were $155.1 million for Q4 and $507.1 million for full year 2025. SUNOSI preliminary net product revenue was $36.7 million for Q4 and $124.8 million for full year 2025. SYMBRAVO preliminary sales were $4.1 million for Q4 and $6.6 million for full year 2025 after its June 2025 launch. These figures are preliminary, unaudited, and subject to completion of financial close procedures.
Positive
- Total net product revenue $638.5M for full year 2025
- Full year revenue growth of 66% year-over-year
- AUVELITY full year sales of $507.1M
- SUNOSI full year revenue of $124.8M
Negative
- Preliminary unaudited figures subject to change after closing procedures
- SYMBRAVO full year sales were only $6.6M following June 2025 launch
News Market Reaction
On the day this news was published, AXSM gained 4.39%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AXSM was up 1.09% with mixed peer moves: LEGN (+2.12%), NUVL (+1.55%), RYTM (+3.72%) higher, while CYTK (-2.48%) and ABVX (-3.56%) fell. Momentum scanner only flagged ABVX moving up, suggesting this revenue update was stock-specific rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Regulatory update | Positive | +22.8% | FDA accepted sNDA for AXS-05 with Priority Review and set PDUFA date. |
| Dec 31 | Regulatory update | Positive | +22.8% | FDA pre-NDA meeting minutes supported AXS-12 NDA submission in narcolepsy. |
| Nov 20 | Investor conferences | Neutral | -2.4% | Participation in December investor conferences and related webcast availability. |
| Nov 06 | Pipeline acquisition | Positive | +2.7% | Acquisition of AZD7325 rights for epilepsy to advance into Phase 2-enabling work. |
| Nov 03 | Earnings update | Positive | +0.6% | Reported strong Q3 2025 product revenue growth and detailed pipeline progress. |
Recent fundamentally positive updates, especially regulatory and pipeline milestones, have often coincided with positive share price reactions.
Over the past few months, Axsome has combined strong commercial growth with important pipeline and regulatory milestones. On Dec 31, 2025, the FDA accepted a Priority Review sNDA for AXS-05 in Alzheimer’s agitation and separately supported an NDA submission for AXS-12 in narcolepsy, both followed by a +22.75% move. Earlier, Q3 2025 results showed robust revenue growth and an expanding CNS pipeline. Today’s preliminary 4Q and full-year 2025 revenue update continues that trajectory of scaling AUVELITY, SUNOSI, and SYMBRAVO.
Market Pulse Summary
This announcement highlights strong preliminary commercial performance, with 4Q and full-year 2025 net product revenues of $196.0M and $638.5M, representing 65% and 66% annual growth. AUVELITY contributed $507.1M for the year, while SUNOSI and newly launched SYMBRAVO added meaningful revenue. The figures are unaudited and subject to closing adjustments, so investors should watch the final 2025 filing, updated profitability metrics, and any guidance that accompanies the formal results.
AI-generated analysis. Not financial advice.
Total preliminary 4Q and full year 2025 net product revenue of
AUVELITY® preliminary 4Q and full year 2025 net product sales of
SUNOSI® preliminary 4Q and full year 2025 net product revenue of
SYMBRAVO® preliminary 4Q and full year 2025 net product sales of
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary fourth quarter and full year 2025 net product revenues for AUVELITY, SUNOSI, and SYMBRAVO.
Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue (Unaudited)
Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately
- AUVELITY net product sales are expected to be approximately
$155.1 million and$507.1 million for the fourth quarter and full year 2025, respectively. - SUNOSI net product revenue is expected to be approximately
$36.7 million and$124.8 million for the fourth quarter and full year 2025, respectively. - SYMBRAVO net product sales are expected to be approximately
$4.1 million and$6.6 million for the fourth quarter and full year 2025, respectively, following its commercial launch in June 2025.
The foregoing information reflects the Company's estimates with respect to net product revenues for AUVELITY, SUNOSI, and SYMBRAVO based on currently available unaudited information. This announcement is not a comprehensive statement of Axsome’s financial results and is subject to completion of Axsome’s financial closing procedures. Axsome’s final financial results will be issued upon completion of its closing procedures and may vary from these preliminary estimates.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ
What were Axsome (AXSM) preliminary total net product revenues for full year 2025?
How much did AUVELITY sell for Q4 and full year 2025 for AXSM?
What were SUNOSI net product revenues reported by Axsome for 2025?
How did SYMBRAVO perform after its June 2025 commercial launch for AXSM?
Are Axsome's January 12, 2026 revenue figures final for AXSM?
